Consultant360Omalizumab Effective in Children with Multiple Food Allergies

Read the original article

A phase 2 clinical trial evaluated the combination of omalizumab with oral immunotherapy (OIT) in children aged 4-15 years with multiple food allergies. The randomized, blinded study demonstrated significantly higher success rates in food challenges among participants receiving omalizumab with OIT compared to placebo, with no serious adverse events reported.

Key Points:

• The study focused specifically on children with multiple food allergies, addressing a critical gap in research that previously centered on single food allergies
• Patient age range spanned from 4 to 15 years, with allergies confirmed through double-blind, placebo-controlled food challenges
• Treatment protocol involved a 16-week administration period, with OIT introduction at week 8
• Success rates showed marked difference: 83% of omalizumab-treated participants passed food challenges versus 33% in placebo group at week 36
• Safety profile remained favorable throughout the study period with no severe or serious adverse events documented

HCN Medical Memo
The combination of omalizumab with OIT presents a promising therapeutic approach for children with multiple food allergies, offering both safety and efficacy advantages over traditional single-intervention strategies.

More on Immunotherapy